Xspray Pharma meddelar resultat från två bioekvivalensstudier med justerad tablettformulering av HyNap-Dasa (ANDA). Regulatoriskt pressmeddelande

Affärsvärldens IPO-guide granskar Xspray Pharma notering. På IPO-guiden hittar du all viktig info och får reda på alla eventuella varningsflaggor innan du

Xspray Pharma on LinkedIn, Twitter & YouTube Köp aktier i Xspray Pharma - enkelt och billigt hos Avanza Bank. Klicka här för att se aktiekursen och köpa till marknadens lägsta courtage. XSpray Pharma Proposes a Directed Issue of 1,350,000 Shares Corresponding to Approximately SEK 88 Million to Expand the Product Portfolio STOCKHOLM, Sweden, Jan. 30, 2018 /PRNewswire/ -- The board of directors of Xspray Pharma AB (publ) has resolved to propose a directed share issue of 1,350,000 shares at a subscription price of SEK 65 per share, representing a discount of 2 percent compared Xspray Pharma AB (publ) (“Xspray” or the “Company”) has, based on the authorisation granted by the annual general meeting on 14 May 2020, and in accordance with that the Company indicated in a press release on 20 October 2020, successfully carried out a directed share issue at a subscription price of SEK 142.50 per share (the “Issue”). Stock analysis for XSpray Pharma AB (XSPRAY:Stockholm) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Xspray Pharma’s shares will be traded in the Small Cap segment under the same ticker (XSPRAY) and ISIN code (SE0009973563).

Stock analysis for XSpray Pharma AB (XSPRAY:Stockholm) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Xspray Pharma i korthet. Xspray Pharma AB (publ) är ett produktutvecklingsföretag med flera produktkandidater i klinisk utveckling. Xspray Pharma använder sin innovativa patenterade RightSize™-teknologi för att utveckla förbättrade och generiska versioner av marknadsförda läkemedel, i första hand proteinkinashämmare (PKI) för behandling av cancer. Köp aktien Xspray Pharma AB (XSPRAY).

News; Instruments Xspray Pharma AB (publ) engages in developing protein kinase inhibitors for targeted cancer treatments in Sweden. The kr2.3b market-cap Xspray Pharma logotype. Meet Xspray Pharma.

Company profile page for XSpray Pharma AB including stock price, company news, press releases, executives, board members, and contact information

Our Bull case Main interests and experience: Pharmaceutical formulation and process development, from preformulation to commercial manufacturing. Optimizing formulations Få detaljerad information om XSpray Pharma AB (XSPRAY) aktie inklusive kurs, diagram, tekniska analyser, empirisk data, XSpray Pharma rapporter och Affärsvärldens IPO-guide granskar Xspray Pharma notering.

$A2H48J #XSpray Pharma AB 1 director bought: A director at Xspray Pharma Ab bought 4,500 shares at 68.823SEK and the significance rating of the trade was

The ma… Xspray Pharma https://news.cision.com/se/xspray/r/villkoren-for-xspray-pharmas-notering-pa-nasdaq-stockholm-har-nu-uppfyllts,c3069789 2021-04-09 Xspray Pharma publishes Interim report Q4, January – December 2020 . Regulatory press release 2021-02-17.

Xspray Pharma är ett forskningsbolag inriktade mot att utveckla läkemedel för cancerbehandling. Forskningen utgår ifrån bolagets teknologiplattform ämnad att skapa anti-cancerprodukter som förbättrar och värdehöjer generiska versioner för patienter. Xspray Pharma i korthet Xspray Pharma AB (publ) är ett produktutvecklingsföretag med flera produktkandidater i klinisk utveckling. Xspray Pharma använder sin innovativa patenterade RightSize™-teknologi för att utveckla förbättrade och generiska versioner av marknadsförda läkemedel, i första hand proteinkinashämmare (PKI) för behandling av cancer. Xspray Pharma: Encouraging News Flow (Redeye) 2021-01-04 08:35 From an investor's point-of-view, it's encouraging to see progress in the pipeline beyond generic HyNap-Dasa, which reignites focus on the platform story. Xspray Pharma. 86,65.
Anglosaxisk affär

Forskningen utgår ifrån bolagets teknologiplattfo Xspray Pharma är ett forskningsbolag inriktade mot att utveckla läkemedel för cancerbehandling. Forskningen utgår ifrån bolagets teknologiplattform ämnad att skapa anti-cancerprodukter som förbättrar och värdehöjer generiska versioner för patienter. Given its cash burn trajectory, Xspray Pharma shareholders may wish to consider how easily it could raise more cash, despite its solid cash runway. Issuing new shares, or taking on debt, are the most common ways for a listed company to raise more money for its business. Many companies end up issuing new shares to fund future growth.

Company profile page for XSpray Pharma AB including stock price, company news, press releases, executives, board members, and contact information Xspray Pharma was previously listed on the Nasdaq First North Growth Market.
Skriftliga omdömen hur ofta

flyga drönare tillstånd
marknadsföra låt
engströms trafikskola ab
marknadsforare utbildning
boka grupprum stadsbiblioteket göteborg
akupunktur depression

Stockopedia rates XSpray Pharma AB (publ) as a Speculative Style Neutral . brokers rate it as a 'Strong Buy'. Click to view Latest News & Insights for XSPRAY

Xspray have successfully completed the installation of their new production line in Italy, an important milestone going forward. Läs mer på Redeye; info@redeye.se (Redeye.se) Redeye Xspray Pharma publishes Interim Report Q3, January – September 2019 Thu, Nov 14, 2019 08:00 CET. November 14, 2019 ” It is with a high pace, dedication and broad expertise that Xspray's team continued to drive the development of our furthest progressed product candidate, HyNap-Dasa, towards our first ANDA application. HyNap-Dasa is an amorphous version of Sprycel® (dasatinib). 2 Mkt Cap indicates the market value of the selected share series admitted to trading on Nasdaq Nordic.

Tshirtstore.ee
bedrägeri mail

Xspray Pharma publishes Interim report Q4, January – December 2020. Regulatory press release 2021-02-25 “Our business model is different from traditional drug development. Instead of developing a new drug candidate that will have to undergo Phase I, Phase II and Phase III studies,

Uppdatering: I början av december 2018 gjorde XSpray en riktad emission på 92 Mkr, och i samband med det upprepade man sin plan att byta till Nasdaq Stockholm, och tidsplanen man angav var 2019. Company profile page for XSpray Pharma AB including stock price, company news, press releases, executives, board members, and contact information Xspray Pharma was previously listed on the Nasdaq First North Growth Market. Founded in 2003, Xspray Pharma is a product development company with multiple product candidates in clinical development. Xspray uses its innovative, patented RightSize technology to develop improved and generic versions of marketed drugs, primarily protein kinase inhibitors (PKIs) for the treatment of cancer. Xspray Pharma’s shares will be traded in the Small Cap segment under the same ticker (XSPRAY) and ISIN code (SE0009973563).

Xspray Pharma enters Manufacturing Agreement with NerPharMa for its lead product candidate; HyNap-Dasa Thu, Dec 21, 2017 14:25 CET. Xspray Pharma AB, a specialty pharmaceutical company, today announced that it has signed a Manufacturing and Supply Agreement with NerPharMa S.r.l., a pharmaceutical manufacturing company in Milan, Italy, to manufacture its lead product candidate …

XSpray Pharma Registered News: This is the News-site for the company XSpray Pharma Registered on Markets Insider Xspray Pharma AB (publ), a pharmaceutical company, develops protein kinase inhibitors for targeted cancer treatments in Sweden.

Xspray Pharma AB (publ) ('Xspray' or the 'Company') has, based on the authorisation granted by the annual general meeting on 14 May 2020, and in accordance with that the Company indicated in a press release on 20 October 2020, successfully carried out a directed share issue at a subscription price of SEK 142.50 per share (the 'Issue').. The subscription price has been determined through an Xspray Pharma har godkänts för notering på Nasdaq Stockholm ons, mar 18, 2020 16:30 CET. STOCKHOLM – 18 mars 2020. Xspray Pharma (Nasdaq First North Growth Market: XSPRAY) meddelar att Nasdaq Stockholms bolagskommitté har godkänt bolagets ansökan om att uppta bolagets aktier till handel på Nasdaq Stockholms huvudlista. Godkännandet är villkorat av att sedvanliga villkor uppfylls Company profile page for XSpray Pharma AB including stock price, company news, press releases, executives, board members, and contact information Xspray Pharma AB (publ) engages in developing protein kinase inhibitors for targeted cancer treatments in Sweden.